Evotec forms collaboration with Petra Pharma on INDiGO platform

Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business ...

Topics: Corporate, INDiGO Read More

Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic

INDiGO® is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks.

Topics: Corporate, INDiGO Read More